Key result
Combretastatin-based chemotherapy linked to reversible myocardial stunning in 2 patients.
Why the study?
Myocardial stunning has been reported after many extracardiac stressors but not following chemotherapy with combretastatin-based combined modality therapy.
Case Report (n=2)
Combretastatin-based chemotherapy may induce transient myocardial stunning (stress cardiomyopathy), highlighting the need for cardiovascular monitoring in these patients.
Answers are grounded in this paper and cite their sources.
May warrant cardiac monitoring with combretastatin; hypothesis-generating case report requiring prospective validation.
Myocardial stunning, known as stress cardiomyopathy, broken-heart syndrome, transient left ventricular apical ballooning, and Takotsubo cardiomyopathy, has been reported after many extracardiac stressors, but not following chemotherapy. We report 2 cases with characteristic electrocardiographic and echocardiographic features following combined modality therapy with combretastatin, a vascular-disrupting agent being studied for treatment of anaplastic thyroid cancer. In 1 patient, an ECG performed per protocol 18 hours after drug initiation showed deep, symmetric T-wave inversions in limb leads I and aVL and precordial leads V(2) through V(6). Echocardiography showed mildly reduced overall left ventricular systolic function with akinesis of the entire apex. The patient had mild elevations of troponin I. Coronary angiography revealed no epicardial coronary artery disease. The electrocardiographic and echocardiographic abnormalities resolved after several weeks. The patient remains stable from a cardiovascular standpoint and has not had a recurrence during follow-up. An electrocardiogram performed per protocol in a second patient showed deep, symmetric T-wave inversions throughout the precordial leads and a prolonged QT interval. Echocardiography showed mildly reduced left ventricular function with hypokinesis of the apical-septal wall. Acute coronary syndrome was ruled out, and both the electrocardiographic and echocardiographic changes resolved at follow-up. Although the patient remained pain-free without recurrence of anginal symptoms during long-term follow-up, the patient developed progressive malignancy and died.
No takes yet. Share an insight, caveat, or question.
Bhakta et al. (2009) conducted a case report in Anaplastic thyroid cancer / Myocardial stunning (n=2). Combretastatin-based chemotherapy was evaluated on Myocardial stunning (electrocardiographic and echocardiographic features). Combretastatin-based chemotherapy was associated with myocardial stunning, presenting with reversible electrocardiographic and echocardiographic abnormalities in 2 patients.
Synapse has enriched 10 related papers. Consider them for comparative context: